{"id":212731,"date":"2025-04-29T09:12:12","date_gmt":"2025-04-29T14:12:12","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/04\/novel-car-t-therapy-achieves-positive-results-in-a-high-proportion-of-patients-with-a-refractory-type-of-lymphoma"},"modified":"2025-04-29T09:12:12","modified_gmt":"2025-04-29T14:12:12","slug":"novel-car-t-therapy-achieves-positive-results-in-a-high-proportion-of-patients-with-a-refractory-type-of-lymphoma","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/04\/novel-car-t-therapy-achieves-positive-results-in-a-high-proportion-of-patients-with-a-refractory-type-of-lymphoma","title":{"rendered":"Novel CAR-T therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/novel-car-t-therapy-achieves-positive-results-in-a-high-proportion-of-patients-with-a-refractory-type-of-lymphoma.jpg\"><\/a><\/p>\n<p>Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukemia Research Institute, have developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma.<\/p>\n<p>A Phase I clinical trial, whose results have been <a href=\"https:\/\/ashpublications.org\/blood\/article\/145\/16\/1788\/535236\/HSP-CAR30-with-a-high-proportion-of-less\" target=\"_blank\">published<\/a> in the journal <i>Blood<\/i>, reveals that this new CAR-T30 therapy promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients.<\/p>\n<p>Hodgkin <a href=\"https:\/\/medicalxpress.com\/tags\/lymphoma\/\" rel=\"tag\" class=\"\">lymphoma<\/a> and other CD30<sup>+<\/sup> lymphomas have posed a significant challenge to the medical community, particularly in refractory or relapsed cases where conventional treatments have so far shown limited efficacy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukemia Research Institute, have developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma. A Phase I clinical trial, whose results have been [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-212731","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/212731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=212731"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/212731\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=212731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=212731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=212731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}